Advertisement

Functional Studies on Steroid Receptors

  • Simon Schlanger
  • Hannelore V. HeemersEmail author
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1786)

Abstract

Nuclear receptors play an important role in prostate cancer and the androgen receptor is a key transcription factor in regulation of cellular events. Androgen receptor-associated coregulators may be upregulated or downregulated in prostate cancer. Altered expression of regulators may potentiate androgen-induced proliferation, migration, and invasion. Therapies aimed to modulate the function of coregulators in prostate cancer may be based on the use of small molecule inhibitors. Expression and function of AR-associated proteins could be investigated after overexpression and gene silencing followed by hormonal treatment, real-time RT-PCR and ChIP.

Key words

Androgen receptor Coregulatory proteins Transcriptional complexes Prostate cancer progression 

References

  1. 1.
    Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64(1):9–29CrossRefPubMedGoogle Scholar
  2. 2.
    Denmeade SR, Isaacs JT (2002) A history of prostate cancer treatment. Nat Rev Cancer 2(5):389–396CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Schmidt LJ, Tindall DJ (2013) Androgen receptor: past, present and future. Curr Drug Targets 14(4):401–407CrossRefPubMedGoogle Scholar
  4. 4.
    Heemers HV, Tindall DJ (2007) Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev 28(7):778–808CrossRefPubMedGoogle Scholar
  5. 5.
    Nguyen PL, Alibhai SM, Basaria S et al (2014) Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol 67:825–836CrossRefPubMedGoogle Scholar
  6. 6.
    Elbanna M, Heemers HV (2014) Alternative approaches to prevent androgen action in prostate cancer: are we there yet? Discov Med 17(95):267–274PubMedGoogle Scholar
  7. 7.
    Heemers HV (2014) Targeting androgen receptor action for prostate cancer treatment: does the post-receptor level provide novel opportunities? Int J Biol Sci 10(6):576–587CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Cancer Biology, Cleveland ClinicLerner Research InstituteClevelandUSA
  2. 2.Department of Urology, Cleveland ClinicGlickman Urologic & Kidney InstituteClevelandUSA
  3. 3.Department of Hematology/Medical Oncology, Cleveland ClinicTaussig Cancer InstituteClevelandUSA

Personalised recommendations